|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The NPM/ALK fusion gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protein that containsthe amino-terminal portion of the nucleolar phosphoprotein nucleophosmin(NPM) joined to the entire cytoplasmic portion of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).
|
11522649 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore co-expression of NK and ALCL features supports the concept that a minority of null-ALCL may be derived from NK cells and expands the spectrum of phenotypes that can be seen in tumors produced by ALK fusion proteins.(Blood.2001;98:1209-1216)
|
11493472 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although based on a single case, these data indicate that structural rather than numerical abnormalities of the ALK gene are implicated in the pathogenesis of anaplastic large cell lymphomas.
|
11215285 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK was detected in 21 of 66 (31.8%) ALCLs.
|
11485911 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, of the eight ALK-positive ALCL cases that were strongly positive for the NPM-ALK fusion, three cases also showed the presence of the ATIC-ALK fusion, although at much lower levels.
|
11395396 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To evaluate this entity in a pediatric population, 36 cases of childhood large cell lymphoma were evaluated for abnormalities of the anaplastic lymphoma kinase (ALK) gene that has been associated with ALCL morphology and immunophenotype.
|
11178628 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence in situ hybridization (FISH) showed rearrangement of the ALK gene, which usually results from the t(2;5) translocation, present in most anaplastic large cell lymphomas.
|
11441342 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we have identified the moesin (MSN) gene at Xq11-12 as a new partner of ALK in a case of ALCL which exhibited a distinctive membrane-restricted pattern of ALK labeling.
|
11310834 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The t(2;5)(p23;q35) translocation creates a fusion gene NPM-ALK (p80) that encodes a product with tyrosine kinase activity believed to play an important role in development of anaplastic large cell lymphoma (ALCL).
|
11532349 |
2001 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we used subtractive suppression hybridization to compare gene expression between an ALK-positive anaplastic large cell lymphoma (ALCL)-derived cell line and a clinical case of ALK-negative ALCL.
|
12181047 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Accumulating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5) translocation that creates an NPM-ALK fusion gene, defines a distinct type of T/null-cell lymphoma (TCL) within a vastly heterogeneous group of anaplastic large cell lymphomas.
|
14569815 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Not all tumors classified as ALCLs have ALK rearrangements and, conversely, ALK rearrangements occur in lymphomas of widely varying morphology.
|
12202671 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.
|
11943732 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, full length receptor expression is absent in cell lines of the hematopoietic system with the exception of t(2;5)-associated anaplastic large cell lymphomas lines (ALCL), which are known to express chimeric NPM-ALK mRNA.
|
12115586 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).
|
12112524 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
This prognostic effect was strongly related to anaplastic lymphoma kinase (ALK) status: ALK-positive ALCL had significantly higher levels of active caspase 3, while high expression of the antiapoptotic proteins Bcl-2 and PI9 was almost completely restricted to ALK-negative cases.
|
12036886 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).
|
12112524 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) exhibiting the t(2;5) translocation is characterized by the resulting expression of the oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) gene product.
|
11801565 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
C-Myc may be a downstream target of ALK signaling and its expression a defining characteristic of ALK-positive ALCLs.
|
12213716 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Epstein-Barr virus association and ALK gene expression in anaplastic large-cell lymphoma.
|
11957137 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ribozyme performance was tested in 293 cells (cotransfected with NPM-ALK) and in the ALCL cell line Karpas 299 by transient and stable transfection and Western blotting.
|
12644020 |
2003 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
|
12800156 |
2003 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, while anaplastic lymphoma kinase-positive ALCL and young patient age generally are associated with a favorable prognosis, leukemic involvement seems to identify a high-risk malignant neoplasm that requires more aggressive therapy, including hematopoietic stem cell transplantation.
|
14560573 |
2003 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CLTC encodes a major subunit of clathrin, a multimeric protein on cytoplasmic organelles, and is a known recurrent fusion partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors.
|
12917640 |
2003 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using a 10% cutoff, p27 was positive in 12 of 66 (18.2%) ALCL tumors (5 ALK positive and 7 ALK negative), whereas JAB1 was detected in 47 of 53 (88.7%) tumors (15 ALK positive and 32 ALK negative) assessed. p27 and JAB1 expression were inversely correlated (Spearman r = -0.27, P = 0.03).
|
12631617 |
2003 |